JP2021534253A5 - - Google Patents

Info

Publication number
JP2021534253A5
JP2021534253A5 JP2021532537A JP2021532537A JP2021534253A5 JP 2021534253 A5 JP2021534253 A5 JP 2021534253A5 JP 2021532537 A JP2021532537 A JP 2021532537A JP 2021532537 A JP2021532537 A JP 2021532537A JP 2021534253 A5 JP2021534253 A5 JP 2021534253A5
Authority
JP
Japan
Prior art keywords
approximately
pharmaceutical composition
composition according
bendamustine
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021532537A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534253A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/056903 external-priority patent/WO2020035806A1/en
Publication of JP2021534253A publication Critical patent/JP2021534253A/ja
Publication of JP2021534253A5 publication Critical patent/JP2021534253A5/ja
Priority to JP2024086001A priority Critical patent/JP2024109878A/ja
Withdrawn legal-status Critical Current

Links

JP2021532537A 2018-08-17 2019-08-14 液体ベンダムスチン医薬組成物 Withdrawn JP2021534253A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024086001A JP2024109878A (ja) 2018-08-17 2024-05-28 液体ベンダムスチン医薬組成物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862764975P 2018-08-17 2018-08-17
US62/764,975 2018-08-17
US201862723725P 2018-08-28 2018-08-28
US62/723,725 2018-08-28
US201962815376P 2019-03-08 2019-03-08
US62/815,376 2019-03-08
PCT/IB2019/056903 WO2020035806A1 (en) 2018-08-17 2019-08-14 Liquid bendamustine pharmaceutical compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024086001A Division JP2024109878A (ja) 2018-08-17 2024-05-28 液体ベンダムスチン医薬組成物

Publications (2)

Publication Number Publication Date
JP2021534253A JP2021534253A (ja) 2021-12-09
JP2021534253A5 true JP2021534253A5 (OSRAM) 2022-08-10

Family

ID=69525233

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021532537A Withdrawn JP2021534253A (ja) 2018-08-17 2019-08-14 液体ベンダムスチン医薬組成物
JP2024086001A Withdrawn JP2024109878A (ja) 2018-08-17 2024-05-28 液体ベンダムスチン医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024086001A Withdrawn JP2024109878A (ja) 2018-08-17 2024-05-28 液体ベンダムスチン医薬組成物

Country Status (7)

Country Link
US (1) US12246007B2 (OSRAM)
EP (1) EP3836921B1 (OSRAM)
JP (2) JP2021534253A (OSRAM)
AU (1) AU2019321089A1 (OSRAM)
CA (1) CA3108321A1 (OSRAM)
ES (1) ES3055021T3 (OSRAM)
WO (1) WO2020035806A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020081148A1 (en) 2018-10-16 2020-04-23 US Nano Food & Drug INC Intratumor injection formulation
US11730815B2 (en) 2018-11-26 2023-08-22 Good Health, Llc Stable liquid pharmaceutical compositions comprising bendamustine
CN114929213A (zh) * 2020-04-13 2022-08-19 美国纳米食品药品公司 碱性化疗药瘤内注射剂组合物
AU2021256189A1 (en) * 2020-04-15 2022-11-10 Kashiv Biosciences, Llc Stable ready to dilute formulations of carfilzomib
GB202118175D0 (en) 2021-12-15 2022-01-26 Arecor Ltd Novel composition
US11707450B1 (en) 2022-03-03 2023-07-25 Slayback Pharma Llc Stable pharmaceutical compositions of bendamustine
CN118415976A (zh) * 2024-05-09 2024-08-02 深圳开悦生命科技有限公司 多环化合物注射剂及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
WO2010036702A1 (en) * 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
ES2609106T5 (es) 2010-01-28 2020-11-10 Eagle Pharmaceuticals Inc Formulaciones de bendamustina
US20130210878A1 (en) 2012-01-24 2013-08-15 Innopharma, Inc. Bendamustine compositions and methods therefore
DK3533447T3 (da) 2012-03-20 2023-04-24 Eagle Pharmaceuticals Inc Flydende bendamustinsammensætninger til anvendelse i fremgangsmåde til behandling af bendamustin-responsive tilstande hos patienter som kræver reducerede volumener til indgivelse
FI2827862T3 (fi) 2012-03-20 2024-02-13 Eagle Pharmaceuticals Inc Bendamustiinin formulaatioita
US20160235717A1 (en) * 2013-10-11 2016-08-18 Luitpold Pharmaceuticals, Inc. Bendamustine pharmaceutical compositions
WO2016005995A2 (en) * 2014-07-10 2016-01-14 Leiutis Pharmaceuticals Pvt. Ltd. Glycol free stable liquid compositions of bendamustine
WO2016059590A1 (en) 2014-10-16 2016-04-21 Piramal Enterprises Limited Stable injectable composition of small molecule drugs and process for its preparation
US9603930B2 (en) 2014-12-04 2017-03-28 Navinta, Llc Liquid bendamustine formulation
CN110772480B (zh) * 2016-03-25 2022-05-17 南京百劲企业管理咨询有限公司 苯达莫司汀药剂组合物及应用
WO2017175098A1 (en) * 2016-04-05 2017-10-12 Leiutis Pharmaceuticals Pvt Ltd Stable liquid pharmaceutical formulations of bendamustine
US10905677B2 (en) * 2016-08-31 2021-02-02 Navinta, Llc Bendamustine solution formulations

Similar Documents

Publication Publication Date Title
US12350257B2 (en) Formulations of bendamustine
CN102164579B (zh) 苯达莫司汀的液体配制品
CN104203235B (zh) 苯达莫司汀的制剂
JP2015506989A5 (OSRAM)
AR086115A1 (es) Formulaciones parenterales mejoradas de agentes farmaceuticos lipofilos y los metodos para la preparacion y el uso de las mismas
EP2588084B1 (en) Antibiotic compositions comprising tulathromycin
JP2024109878A (ja) 液体ベンダムスチン医薬組成物
US9603930B2 (en) Liquid bendamustine formulation
AR085273A1 (es) Formulacion liquida libre de propelente que comprende una droga antimuscarinica
WO2017175098A1 (en) Stable liquid pharmaceutical formulations of bendamustine
WO2016005995A2 (en) Glycol free stable liquid compositions of bendamustine
US20240009199A1 (en) Pemetrexed formulations
Kapetanovic et al. Pharmacokinetics and enhanced bioavailability of candidate cancer preventative agent, SR13668 in dogs and monkeys
JPWO2018056336A1 (ja) ペメトレキセド製剤
US20190070136A1 (en) Parenteral compositions of carmustine
CN115666652A (zh) 聚醚系化合物的用途
AU2023202089B2 (en) Pemetrexed formulations
JP2017057202A (ja) ボルテゾミブ含有凍結乾燥医薬組成物およびその製造方法
US20150320680A1 (en) Injectable composition containing chlorothiazide
WO2021192471A1 (ja) ペメトレキセド製剤
CN105451731A (zh) 含有经稳定化的2-氨基-3-(4-溴苯甲酰基)苯乙酸的水性组合物
JP2011032220A (ja) エダラボン液剤
CN107714651A (zh) 一种非班太尔脂质体及其制备方法
TH95332A (th) สูตรผสมชนิดแอคเควียสเจล ซึ่งมี 1-(2-เมธิลโพรพิล)-1H-อิมิดาโซ[4,5-c][1,5]แนฟธิริดิน-4-แอมีน